Next-IO™ Anti-TMIGD2 Monoclonal Antibody Program

About This Program

This program aims to develop therapeutic monoclonal antibody against the target – TMIGD2 (CD134).

Transmembrane and immunoglobulin domain containing 2 (TMIGD2) is a novel immune checkpoint molecule of the B7:CD28 family, however, little research has been done on this molecule. In this case, the highlight of this program is to use TMIGD2 as a novel potential therapeutic target in the field of immuno-oncology.

TMIGD2

TMIGD2 (IGPR-1/CD28H) is a HHLA2 receptor and is normally expressed by naive T cells, majority of natural killer (NK) cells and half of the memory T cells, and it is not expressed by T regulatory cells or B cells, or activated T cells. Multiple studies have shown:

• The HHLA2/TMIGD2 interaction selectively co-stimulates human T cell growth and cytokine production via an AKT-dependent signaling cascade.
• TMIGD2 also plays an important role in cell-cell interactions, cell migration, and angiogenesis

Published Data

• Re-expression of TMIGD1 inhibits renal tumor growth.

Fig.1 Re-expression of TMIGD1 inhibits renal tumor growth.¹

Indication

Up to today, only one published paper in 2018 stated that TMIGD2 may be a potential target for renal cell carcinoma (RCC). Further studies are required to dissect TMIGD2’s expression patterns and functions in cancer.

Clinical Trials under Progress

Currently, only a few clinical studies are investigating the roles of TMIGD2. Further studies are required to develop new therapies targeting TMIGD2. Our program will be a pioneer in the field of anti-TMIGD2 therapeutic monoclonal development.

Program Plan

With our extensive experience in providing CRO services, we are confident in providing streamlined end-to-end program. We are committed to developing the complete program, which tailors to the needs of our partners, from antibody discovery, engineering, optimization, to pre-clinical studies. Periodic progress reports will be delivered to our clients for effective, smooth and timely communication.

Fig.2 The timeline of Next-IOᵀᴹ programs.

Collaboration

Creative Biolabs is looking for potential partners (including but not limited to major pharma or biotech firms) to develop anti- TMIGD2 monoclonal antibody program together. Our scientists are dedicated to bringing years of valuable experience to our partner and enabling a meaningful partnership. By using this strategic collaboration, we wish to help both sides to proceed with IND and many stages of clinical trials beyond.

If you are interested in our program, please feel free to contact us to learn more details about the cooperation. Looking forward to working with you in the near future.

Reference

• Meyer R D., et al. TMIGD1 acts as a tumor suppressor through regulation of p21Cip1/p27Kip1 in renal cancer[J]. Oncotarget, 2018, 9(11):9672-9684.